Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy
[Journal for ImmunoTherapy of Cancer] Microarray data and immunopeptidomics were used to identify candidate antigens for immunization in 5T multiple myeloma models.
Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors
[Cancer Discovery] Investigators take an inventory of the current state of the pediatric central nervous system CAR T-cell field through the lens of translational obstacles to broader clinical success.
Chimeric Brain Models: Unlocking Insights into Human Neural Development, Aging, Diseases, and Cell Therapies
[Neuron] The authors highlight recent advancements in using chimeric models to study human neural development, aging, and disease.
CLDN18.2-Targeting STAR-T Cell Therapy for Pancreatic Cancer: A Strategy to Minimize Gastric Off-Tumor Toxicity Compared to CLDN18.2 CAR-T
[Oncogene] Scientists developed CLDN18.2-specific synthetic T cell receptor and antigen receptor T (STAR-T) cells. They showed that STAR-T and CAR-T cells have comparable in vitro cytotoxicity, but STAR-T cells caused less gastric damage in vivo despite having weaker antitumor effects than CAR-T cells.
Repurposing Anti-Viral Subunit and mRNA Vaccines T Cell Immunity for Intratumoral Immunotherapy against Solid Tumors
[npj Vaccines] Scientists investigated intratumoral delivery of three licensed viral vaccines— Shingrix, Gardasil-9, and Spikevax —in prevaccinated mice using the murine tumor model TC-1, which expressed HPV16 oncogenes E6 and E7.
Novel Humanized CD19-CAR-T (Now Talicabtagene Autoleucel, Tali-Cel™) Cells in Relapsed/ Refractory Pediatric B-Acute Lymphoblastic leukemia- an Open-Label Single-Arm Phase-I/Ib Study
[Blood Cancer Journal] Investigators developed a novel humanized CD19-directed CAR-T approved for Phase I/Ib/II trials. Patients aged 3–25 years were enrolled with relapsed/refractory B-acute lymphoblastic leukemia and ineligible for allogeneic stem cell transplant.
HHV-6 and HHV-7 Reactivation in Allogeneic CAR-T Cell Therapy
[Trends in Biotechnology] Scientists explore human herpesviruses 6 and 7 (HHV-6 and HHV-7) reactivations in CAR-T cell therapy and discuss mitigation strategies during allogeneic CAR-T cell manufacturing.
Bridging Intensity Is Associated with Impaired Hematopoietic Recovery following BCMA CAR-T Therapy for Multiple Myeloma
[Blood Advances] In this multicenter international observational study, researchers explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with relapsed/refractory multiple myeloma treated with B-cell maturation antigen-directed CAR T-cell therapy.
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
[JAMA Oncology] In this Phase II, single-arm, nonrandomized clinical trial that included 28 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, the complete molecular remission rate after CD19 chimeric antigen receptor (CAR) T cell therapy was 85%.
Dual Modulation of Cytotoxic and Checkpoint Receptors Tunes the Efficacy of Adoptive Delta One T Cell Therapy against Colorectal Cancer
[Nature Cancer] Investigators demonstrated the capacity of Delta One T cells to target colorectal cancer (CRC) cell lines and patient-derived specimens and organoids in vitro and to control tumor growth in an orthotopic xenograft model of CRC.
Overcoming Extracellular Vesicle-Mediated Fratricide Improves CAR T Cell Treatment against Solid Tumors
[Nature Cancer] The authors reported that solid tumors responded to CAR T cells by upregulating the secretion of small extracellular vesicles carrying tumor antigens, which were horizontally transferred to CAR T cells, leading to antigen recognition and CAR T cell fratricide.
AAV1 CFTR Preferentially Transduces Cysts and Reduces Cyst Size in a Mouse Model of ADPKD
[American Journal of Physiology - Cell Physiology] To overcome the challenges of developing a gene therapy for ADPKD, scientists focused on the surface receptors expressed in cystic epithelia.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
